Ondine Biomedical Inc. (AIM:OBI)
13.75
0.00 (0.00%)
Oct 10, 2025, 3:49 PM GMT+1
Ondine Biomedical Revenue
Ondine Biomedical had revenue of 1.01M CAD in the half year ending June 30, 2025, with 136.68% growth. This brings the company's revenue in the last twelve months to 2.20M, up 34.82% year-over-year. In the year 2024, Ondine Biomedical had annual revenue of 2.05M with 70.32% growth.
Revenue (ttm)
2.20M CAD
Revenue Growth
+34.82%
P/S Ratio
51.81
Revenue / Employee
122.39K CAD
Employees
18
Market Cap
61.08M GBP
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.05M | 846.00K | 70.32% |
Dec 31, 2023 | 1.20M | 565.00K | 88.56% |
Dec 31, 2022 | 638.00K | -1.93M | -75.17% |
Dec 31, 2021 | 2.57M | 778.00K | 43.44% |
Dec 31, 2020 | 1.79M | 258.16K | 16.84% |
Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |